Type Two diabetes breakthrough

Scientists have produced a new pill that assist patients shed weight from their waistlines and can halt type 2 diabetes, a study has revealed.

Results from an individual trial of 632 patients discovered semaglutide allowed 71 percent of these to shed pounds – it’s thought this is the first type 2 diabetes pill to instigate weight reduction.    

Researchers hope semaglutide will provide a way to control the hidden killer, as weight reduction which fuels type 2 diabetes can be triggered by a few remedies.  

Results from the phase II trial completed from the Leicester Diabetes Centre were published in the JAMA. Semaglutide could be available on the NHS within three years.

The pill was given to patients as an add-on – the drug is the first line of defence to control the preventable illness.  

Researchers found type 2 diabetes ceased slashed blood sugar levels and prevented patients from requiring insulin.

Type 2 diabetes can lead to heart failure, blindness and leg amputations and is termed a worldwide time bomb.  

Spiraling rates have fuelled a 65 percent rise with more than 4 million people now living with the illness, UK data reveals. Globally there are 380 million patients.

Charities have warned the NHS will end up jaded by the burden of the illness without demanding action to make changes to the lifestyles of today.  

Lead author, Professor Melanie Davies, dubbed the results ‘promising’ and stated they reveal ‘semaglutide’s capability support weight reduction and to lower HbA1c’.  

Semaglutide allowed 71 percent of individuals to lose weight, researchers found, as it is Thought to Be the first of its type to shed weight loss (inventory)

Supplying patients some relief 

Lead author Professor Melanie Davies said taking semaglutide for a pill may offer relief to some diabetics ‘fight injecting themselves’.

She told MailOnline: ‘For some patients injectable remedies are a issue, so having something accessible makes it more accessible to some patients.

‘We know that it’s a small barrier to individuals and anything that makes treatment easier and more accessible has got to be seen as good.

Professor Davies added: ‘Type 2 diabetes is a serious illness with potentially catastrophic complications which is currently posing a significant barrier to health services across the world due to the numbers of people.

‘These results demonstrating semaglutide’s capability to have a significant impact on lowering HbA1c when taken orally are hugely promising and support weight loss.’  

Experts have welcomed ‘ findings encouraging.


There are thought to be around 380 million sufferers. In Britain that has topped 3.8 million, a figure that continues to grow.

The World Health Organization issued a warning to say the world is facing ‘a growing diabetes epidemic of proportions’ in 2004.

Since 1996, the amount of individuals has more than doubled. The rapid escalation remains of concern.

Type 2 diabetes is due to having too much sugar in the blood because the body’s method of turning it into energy isn’t working correctly.

As the illness progresses, sufferers often should keep up a mixture of drugs, exercise and a healthy diet to manage it.

Controlling glucose levels are considered to be the key to reducing the danger of life-changing complications for those diagnosed.

Somebody’s life expectancy with type 2 diabetes is likely to be reduced as a result of the condition it’s believed.  

Editor of The Diabetes Times, Oliver Jelley, told MailOnline: ‘Type 2 diabetes has grown into one of the greatest challenges facing the NHS. These latest results are hugely supportive and will be welcomed across the diabetes community.’

Semaglutide is a glucagon-like-peptide-1 (GLP-1) analogue, a relatively new group of injectable drugs. It may be taken orally as a pill.  

It works by stimulating the generation of insulin and controlling the secretion of this hormone glucagon. Appetite is also lowered by the drug.  

How was the research carried out?  

Participants were either provided semaglutide orally or they had been given a placebo. They had been monitored over 26 weeks.

Each volunteer suffered from type 2 diabetes and had a BMI equal or above to 25 – the medical level that deems adults.

What else did they discover?  

In addition to the weight reduction benefits, the researchers also discovered reductions of up to 1.9 percent on average of HbA1c – how blood sugar is measured as time passes.

The findings revealed those of the once weekly injection, and demonstrated considerably better compared to placebo (0.3 percent).

Almost nine tenths of individuals receiving oral semaglutide achieved the target HbA1c level of less than 7 percent.  

Healthy adults have a tendency to have HbA1c levels of below 6 percent, as levels of 6.5 percent or higher can signal diabetes.  

How many sufferers are there?  

Statistics indicate there are 3.8 million sufferers in the UK – with 90 percent with type 2. Drugs to treat the ailments cost the NHS a tenth of its budget.

In the US, there are 29 million girls, using a breakdown between 2 and type 1, with the latter.

Although there are several treatments currently available, many come with risks of developing hypoglycaemia (low blood sugar), as well as weight reduction.

If the condition worsens, insulin injections are needed by patients – .    

Add Comment